Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00918749 · ClinicalTrials.gov registry record · Phase 2

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

A Phase 2 study of Postmenopausal Osteoporosis, sponsored by Warner Chilcott.

Completed
Registry status
Phase 2
Development phase
205
Enrollment target
6
Study locations

NCT00918749: Completed Phase 2 study of Postmenopausal Osteoporosis, sponsored by Warner Chilcott.

NCT00918749 is a Phase 2 study of Postmenopausal Osteoporosis that has completed, run by Warner Chilcott. The registered enrollment target is 205 participants, below the 506-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (59% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00918749, a Phase 2 study of Postmenopausal Osteoporosis, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
Phase 2
Development phase
205 participants
Enrollment target
6
Study locations

Study Summary

Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatment regimens for 3 months.

Primary Outcome

Fasting serum Bone turn-over marker specimen assayed by electochemiluminescence.

Interventions

  • DRUG 150 mg
  • DRUG 75 mg
  • DRUG 100 mg

Study Locations (6)

Florida

  • Research Site - Daytona Beach
  • Research Site - Fort Myers

Texas

  • Research Site - Austin
  • Research Site - Dallas

Hawaii

  • Research Site - Honolulu

Indiana

  • Research Site - Evansville

Trial Details

FieldValue
Enrollment Target 205 participants
Start Date 2009-05
Est. Completion 2009-10
Phase Phase 2
Warner Chilcott

53 total trials

What the finished NCT00918749 record still lists

NCT00918749 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 506-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (59% lower).

The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 3 interventions - of which 150 mg is the first listed.

NCT00918749 lists 6 locations in 4 states (Florida, Texas, Hawaii).

Frequently Asked Questions

What is clinical trial NCT00918749 about?

NCT00918749 is a clinical study titled "Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women". Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatmen...

What is the current status of trial NCT00918749?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2009-05. Estimated completion is 2009-10.

What conditions does trial NCT00918749 study?

This clinical trial studies the following conditions: Postmenopausal Osteoporosis.

What interventions are being tested in trial NCT00918749?

The interventions under investigation include: 150 mg (DRUG), 75 mg (DRUG), 100 mg (DRUG).

Who is sponsoring clinical trial NCT00918749?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00918749 being conducted?

This trial has 6 study locations across Florida, Hawaii, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postmenopausal Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00918749's enrollment target sits among peer trials

205 10th of 14 higher than 5 of 14 other Postmenopausal Osteoporosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Postmenopausal Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03457493 · 205 participants · Phase 1

    The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

  • NCT05134857 · 205 participants · Phase 2

    The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

  • NCT05181891 · 205 participants · Phase 2

    Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

  • NCT05283811 · 205 participants · NA

    Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00918749, the US trial registry maintained by the National Library of Medicine. NCT00918749 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.